title: Venous thromboembolism risk and prophylaxis in the acute hospital care setting--results of the ENDORSE study in Poland.
abstract: BACKGROUND
  Venous thromboembolism (VTE) is the most common preventable cause of in-hospital death. However, the risk of VTE and prophylaxis practices in Polish hospitals are not known.
  
  
  OBJECTIVE
  The ENDORSE study in Poland was part of the global cross-sectional Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting survey with the objective to assess the prevalence of VTE risk in acutely ill medical and surgical patients and to determine the proportion of at-risk patients who receive recommended prophylaxis.
  
  
  METHODS
  In 10 non-academic Polish hospitals, a chart review was performed in all inpatients aged 40 or older admitted to medical wards, and in patients at the age of > or = 18 admitted to surgical wards. The VTE risk and recommended prophylaxis were assessed according to the 2004 American College of Chest Physicians (ACCP) guidelines.
  
  
  RESULTS
  The study enrolled 2673 patients (1092 in surgical wards, 1581 in medical wards). Out of these, 1111 were judged to be at risk for VTE (597 surgical patients, 514 medical patients). Only 51.8% of all at-risk patients received ACCP-recommended VTE prophylaxis (54.7% of surgical patients, 32.5% of medical patients).
  
  
  CONCLUSIONS
  In Polish hospitals more than 40% of patients hospitalized for acute illness are at risk of VTE, but only a small proportion of them receives appropriate prophylaxis. These results call for decisive actions to ensure that at-risk patients receive recommended VTE prophylaxis.
authors.affiliation: Department of Medicine, Jagiellonian University School of Medicine, Kraków, Poland. mmmusia@cyf-kr.edu.pl
authors.forename: Jacek
authors.initials: J
authors.lastname: Musiał
authors.forename: Wojciech J
authors.initials: WJ
authors.lastname: Sydor
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006761:Hospitals / Q000706:statistics & numerical data; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data*; D008297:Male; D008485:Medical Audit / Q000706:statistics & numerical data*; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D010346:Patient Care Management / Q000706:statistics & numerical data; D011044:Poland / Q000453:epidemiology; D011183:Postoperative Complications / Q000517:prevention & control; D018570:Risk Assessment; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents